Lupin is currently trading at Rs. 1231.90, up by 36.30 points or 3.04% from its previous closing of Rs. 1195.60 on the BSE.
The scrip opened at Rs. 1225.00 and has touched a high and low of Rs. 1241.00 and Rs. 1205.85 respectively. So far 160527 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1,241.00 on 10-May-2021 and a 52 week low of Rs. 817.65 on 08-May-2020.
Last one week high and low of the scrip stood at Rs. 1,241.00 and Rs. 1050.00 respectively. The current market cap of the company is Rs. 55908.41 crore.
The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 40.46% and 12.69% respectively.
Lupin has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in India.
Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in combination with Remdesivir for the treatment of suspect or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients. With a rapid increase in active COVID-19 cases in India, the timely restricted emergency use of Baricitinib will be an important life-saving treatment for patients with moderate to severe symptoms of COVID-19.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.